Cullinan Therapeutics, Inc.
CGEM
$10.50
$0.302.94%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -216.81M | -206.76M | -178.74M | -167.38M | -143.54M |
| Total Depreciation and Amortization | 309.00K | 306.00K | 306.00K | 306.00K | 306.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.48M | 25.87M | 24.50M | 22.16M | 18.33M |
| Change in Net Operating Assets | 12.76M | 9.06M | 3.72M | -389.00K | -1.90M |
| Cash from Operations | -174.27M | -171.53M | -150.21M | -145.30M | -126.81M |
| Capital Expenditure | -38.00K | -- | -- | -- | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 173.60M | 126.05M | -112.47M | -136.31M | -100.81M |
| Cash from Investing | 173.56M | 126.05M | -112.47M | -136.31M | -100.81M |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.96M | 3.94M | 269.55M | 270.64M | 269.30M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -656.00K | -4.45M | -4.45M | -4.45M |
| Cash from Financing | 1.96M | 3.28M | 265.10M | 266.19M | 264.85M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.25M | -42.20M | 2.43M | -15.43M | 37.24M |